PTC Therapeutics Inc (PTCT)

Precedente Chiudi:

$25.49

Aprire:

$27

Volume 24 ore:

1.52M

Capitalizzazione di mercato:

$2.19B

Reddito:

$937.82M

Utile/perdita netta:

$-626.60M

Rapporto P/E:

-3.3029

EPS:

-8.65

Flusso di cassa netto:

$-279.04M

1 W Prestazione:

+12.84%

1M Prestazione:

+2.18%

6M Prestazione:

+19.29%

1 anno Prestazione:

-45.31%

Intervallo 1D:

$25.67

$29.27

Portata 52W:

$17.53

$59.84

PTC Therapeutics Inc Stock (PTCT) Company Profile

Nome

PTC Therapeutics Inc

Settore

Healthcare (1191)

Industria

Biotechnology (688)

Telefono

908-222-7000

Indirizzo

100 Corporate Court, South Plainfield, NJ

Dipendente

366

Cinguettio

@PTCBio

Prossima data di guadagno

2024-04-25

Ultimi documenti SEC

PTCT's Discussions on Twitter

PTC Therapeutics Inc Stock (PTCT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-19	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2023-12-08	Iniziato	Wells Fargo	Overweight
2023-10-30	Aggiornamento	Oppenheimer	Perform → Outperform
2023-10-27	Downgrade	Citigroup	Neutral → Sell
2023-10-06	Downgrade	Truist	Buy → Hold
2023-09-18	Downgrade	Citigroup	Buy → Neutral
2023-09-15	Downgrade	Raymond James	Outperform → Underperform
2023-03-17	Iniziato	SVB Securities	Market Perform
2022-12-14	Iniziato	Goldman	Sell
2022-09-12	Iniziato	Jefferies	Buy
2022-09-09	Iniziato	Morgan Stanley	Equal-Weight
2022-09-01	Iniziato	Citigroup	Buy
2022-04-04	Ripresa	Cantor Fitzgerald	Overweight
2021-10-18	Downgrade	BofA Securities	Neutral → Underperform
2021-04-26	Ripresa	Credit Suisse	Neutral
2021-03-29	Aggiornamento	RBC Capital Mkts	Underperform → Sector Perform
2021-02-12	Downgrade	BofA Securities	Buy → Neutral
2021-01-05	Aggiornamento	Citigroup	Neutral → Buy
2020-11-30	Downgrade	RBC Capital Mkts	Sector Perform → Underperform
2020-10-30	Downgrade	Citigroup	Buy → Neutral
2020-10-28	Iniziato	UBS	Neutral
2020-10-07	Aggiornamento	JP Morgan	Neutral → Overweight
2020-08-25	Iniziato	Raymond James	Outperform
2020-04-09	Aggiornamento	Citigroup	Neutral → Buy
2020-02-20	Downgrade	Citigroup	Buy → Neutral
2020-02-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2019-11-12	Iniziato	SunTrust	Buy
2019-05-13	Aggiornamento	BofA/Merrill	Neutral → Buy
2019-04-11	Iniziato	Bernstein	Outperform
2018-10-03	Aggiornamento	BofA/Merrill	Underperform → Neutral
2018-10-01	Iniziato	Cantor Fitzgerald	Overweight
2018-07-19	Iniziato	Credit Suisse	Outperform
2018-06-18	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2018-04-04	Downgrade	Barclays	Equal Weight → Underweight
2018-01-29	Ripresa	RBC Capital Mkts	Sector Perform
2017-11-16	Aggiornamento	JP Morgan	Underweight → Neutral
2017-10-26	Downgrade	BofA/Merrill	Neutral → Underperform
2017-10-09	Downgrade	JP Morgan	Neutral → Underweight

Mostra tutto

PTC Therapeutics Inc Borsa (PTCT) Ultime notizie

Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics

Zacks Investment Research

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

Zacks Investment Research

PTC Therapeutics (PTCT) Up on Positive Regulatory Updates

Zacks Investment Research

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday

Benzinga

Here's What Key Metrics Tell Us About PTC Therapeutics (PTCT) Q4 Earnings

Zacks Investment Research

PTC Therapeutics Inc Azioni (PTCT) Dati Finanziari

PTC Therapeutics Inc (PTCT) Reddito 2024

PTC Therapeutics Inc (PTCT) Reddito netto 2024

PTC Therapeutics Inc (PTCT) Flusso di cassa 2024

PTC Therapeutics Inc (PTCT) Utile per azione 2024

PTC Therapeutics Inc Azioni (PTCT) insider trading